(E)-METHYL 2-(2-((1-(2,4-DICHLORO-5-(PHENYLSULFONAMIDO)PHENYL)-3-METHYL-5-OXO-1H-1,2,4-TRIAZOL-4(5H)-YL)METHYL)PHENYL)-2-(METHOXYIMINO)ACETATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SWZTWWQSHWPXNE-BGABXYSRSA-N
Smiles	CO\N=C(\C(=O)OC)/c1ccccc1CN2C(=NN(C2=O)c3cc(NS(=O)(=O)c4ccccc4)c(Cl)cc3Cl)C
InChI	InChI=1S/C26H23Cl2N5O6S/c1-16-29-33(23-14-22(20(27)13-21(23)28)31-40(36,37)18-10-5-4-6-11-18)26(35)32(16)15-17-9-7-8-12-19(17)24(30-39-3)25(34)38-2/h4-14,31H,15H2,1-3H3/b30-24+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C26H23Cl2N5O6S
Molecular Weight	604.46
AlogP	4.45
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	10.0
Polar Surface Area	138.35
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	40.0

Assay Description	Organism	Bioactivity
Herbicidal activity against Eclipta prostrata assessed as growth inhibition at 150 g/ha	Eclipta prostrata	70.0 %
Herbicidal activity against Amaranthus retroflexus assessed as growth inhibition at 150 g/ha	Amaranthus retroflexus	None
Herbicidal activity against Brassica juncea assessed as growth inhibition at 150 g/ha	Brassica juncea	None
Herbicidal activity against Poa annua assessed as growth inhibition at 150 g/ha	Poa annua	None
Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as growth inhibition at 150 g/ha	Echinochloa crus-galli	None
Herbicidal activity against Digitaria sanguinalis (hairy crabgrass) assessed as growth inhibition at 150 g/ha	Digitaria sanguinalis	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2271763
PubChem	76312536

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).